< Back to previous page
Researcher
Patrick Chaltin
- Disciplines:Laboratory medicine, Palliative care and end-of-life care, Regenerative medicine, Other basic sciences, Other health sciences, Nursing, Other paramedical sciences, Other translational sciences, Other medical and health sciences
Affiliations
- Intellectual Property (Administrative office)
Member
From16 Mar 2006 → 10 Apr 2017 - Department of Microbiology, Immunology and Transplantation (Department)
Member
From15 May 2002 → 31 Oct 2002 - Medicinal Chemistry (Rega Institute) (Division)
Member
From1 Oct 1999 → 14 May 2002
Projects
1 - 10 of 16
- ATP13A2 agonists for Parkinson’s disease therapyFrom1 Mar 2024 → TodayFunding: IOF - technology validation in lab
- PHGDH-ASM: Phosphoglycerate dehydrogenase (PHGDH) activators as novel antiseizure medications (ASM) with dual mode of actionFrom1 Oct 2022 → TodayFunding: IOF - technology validation in lab
- VirusBank platform (state-of-the-art research platform for increased preparedness against viral epidemics and pandemics)From1 Jan 2022 → TodayFunding: Ministery of Economical Affairs
- Targeting transcription factor addiction in acute leukemia (TaTFAL)From1 Oct 2021 → TodayFunding: FWO Strategic Basic Research (SBO)
- Understanding the anti-cancer effects of new YAP/TAZ inhibitors to treat malignant mesotheliomaFrom1 Mar 2021 → TodayFunding: Foundations, funds and other with scientific goal
- MATATUM: Validation and druggability development of macrophage-specific targets in the tumor microenvironment.From1 Jan 2018 → 31 Dec 2021Funding: FWO Strategic Basic Research (SBO)
- Targeting ZEB pathways to tackle aggressive (colorectal) cancer (ZENTACC).From1 Jan 2018 → 31 Dec 2021Funding: FWO Strategic Basic Research (SBO)
- Towards a combined post-exposure prophylaxis and successful treatment of rabies in humansFrom1 Oct 2017 → 30 Sep 2020Funding: FWO research project (including WEAVE projects)
- Valorization of novel strategies for the prevention of viral infection and inhibition of viral replication.From1 Nov 2015 → TodayFunding: IOF - Industrial Research Fund, IOF - mandates
- iKap: Targeting nucleocytoplasmic transport for novel anti-cancer therapy.From1 Oct 2015 → 30 Nov 2019Funding: SBO (Strategic basic research)
Publications
1 - 10 of 44
- A novel irreversible TEAD inhibitor, SWTX-143, blocks Hippo pathway transcriptional output and causes tumor regression in preclinical mesothelioma models.(2023)
Authors: Hanne Hillen, Weronika Kowalczyk, Patrick Chaltin, Georg Halder
Pages: OF1 - OF11 - Stimulation of the atypical chemokine receptor 3 (ACKR3) by a small-molecule agonist attenuates fibrosis in a preclinical liver but not lung injury model(2022)
Authors: Tom Van Loy, Steven De Jonghe, Wouter Dheedene, Patrick Chaltin, Aernout Luttun, Dominique Schols
- Cyclin D2 overexpression drives B1a-derived MCL-like lymphoma in mice(2021)
Authors: Patrick Chaltin
- Combining Cell Envelope Stress Reporter Assays in a Screening Approach to Identify BAM Complex Inhibitors(2021)
Authors: Patrick Chaltin
Pages: 2250 - 2263 - Dual inhibition of SARS-CoV-2 and human rhinovirus with protease inhibitors in clinical development(2021)
Authors: Patrick Chaltin
- Dual inhibition of SARS-CoV-2 and human rhinovirus with protease inhibitors in clinical development(2021)
Authors: Patrick Chaltin
- Novel Class of Chikungunya Virus Small Molecule Inhibitors That Targets the Viral Capping Machinery(2020)
Authors: Rana Abdelnabi, Kim Donckers, Pieter Leyssen, Patrick Chaltin, Johan Neyts, Leen Delang
- Functional expression and pharmacological modulation of TRPM3 in human sensory neurons(2020)
Authors: Laura Vangeel, Katrien De Clercq, Patrick Chaltin, Catherine Verfaillie, Joris Vriens, Thomas Voets
Pages: 2683 - 2695 - Discovery of Indole Derivatives as Novel and Potent Dengue Virus Inhibitors(2018)
Authors: Suzanne Kaptein, Kai Dallmeier, Patrick Chaltin, Johan Neyts
Pages: 8390 - 8401 - Modifying Rap1-signalling by targeting Pde6δ is neuroprotective in models of Alzheimer's disease(2018)
Authors: Wim Dehaen, Joris Winderickx, Patrick Chaltin
Patents
1 - 10 of 10
- Aryl derivatives for treating trpm3 mediated disorders (Inventor)
- Heterocycle derivatives for treating trpm3 mediated disorders (Inventor)
- Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases (Inventor)
- Compounds for the treatment of epilepsy, neurodegenerative disorders and other cns disorders (Inventor)
- Compounds for the treatment of epilepsy, neurodegenerative disorders and other cns disorders (Inventor)
- Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases (Inventor)
- Thieno[2,3-b]pyridine derivatives as viral replication inhibitors (Inventor)
- Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases (Inventor)
- N-((1h-indol-3-yl)-alkyl)-4-benzyl)benzamide and n-((1h-pyrrolo[2,3-b]pyridin-3-yl)-alkyl)-4-benzyl)benzamide derivatives as alpha synuclein aggregation inhibitors for the treatment of neurodegenerative disorders (Inventor)
- Compounds for the treatment of neurodegenerative diseases (Inventor)